Editorial: Mechanism and pharmacodynamic material basis of neurodegenerative disease therapies

Erxi Wu; Ronghu Ke; Dan Qi; Jason H Huang

doi:10.3389/fnins.2023.1254881

Editorial: Mechanism and pharmacodynamic material basis of neurodegenerative disease therapies

Front Neurosci. 2023 Jul 21:17:1254881. doi: 10.3389/fnins.2023.1254881. eCollection 2023.

Authors

Erxi Wu^{1

2

3

4}, Ronghu Ke¹, Dan Qi¹, Jason H Huang^{1

2

5}

Affiliations

¹ Department of Neurosurgery and Neuroscience Institute, Baylor Scott and White Health, Temple, TX, United States.
² Department of Medical Education, Texas A&M University School of Medicine, Temple, TX, United States.
³ Department of Pharmaceutical Science, Texas A&M University School of Pharmacy, College Station, TX, United States.
⁴ Department of Oncology, Livestrong Cancer Institutes, Dell Medical School, The University of Texas at Austin, Austin, TX, United States.
⁵ Department of Neurosurgery, Baylor College of Medicine, Temple, TX, United States.

No abstract available

Keywords: Alzheimer's disease; Parkinson's disease; metabolism; multiomics; natural compounds; neurodegenerative disease; therapies.

Publication types

Editorial

Grants and funding

This work was funded by grants from two Corbett Estate Funds [Nos. 62285-531021-41800 (Cross-talking between oncogenesis and neurodegenerative diseases) and 62285-531021-61800 (Natural Products): recipient EW].